Evogene (NASDAQ:EVGN) Stock Passes Above 50 Day Moving Average of $0.83

Evogene Ltd. (NASDAQ:EVGNGet Free Report)’s stock price passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $0.83 and traded as high as $0.93. Evogene shares last traded at $0.88, with a volume of 225,803 shares traded.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Evogene in a research note on Monday, February 5th. They issued a “sell” rating for the company.

Check Out Our Latest Analysis on Evogene

Evogene Price Performance

The firm has a market cap of $36.58 million, a PE ratio of -1.89 and a beta of 1.46. The firm’s fifty day simple moving average is $0.83 and its two-hundred day simple moving average is $0.71.

Hedge Funds Weigh In On Evogene

Hedge funds have recently modified their holdings of the stock. Silverarc Capital Management LLC purchased a new position in shares of Evogene in the second quarter worth $107,000. Renaissance Technologies LLC lifted its holdings in shares of Evogene by 51.8% in the first quarter. Renaissance Technologies LLC now owns 459,081 shares of the biotechnology company’s stock worth $597,000 after buying an additional 156,716 shares in the last quarter. Walleye Capital LLC purchased a new position in shares of Evogene in the third quarter worth $303,000. Bank of America Corp DE lifted its holdings in shares of Evogene by 49.7% in the first quarter. Bank of America Corp DE now owns 204,521 shares of the biotechnology company’s stock worth $265,000 after buying an additional 67,867 shares in the last quarter. Finally, Vident Investment Advisory LLC lifted its holdings in shares of Evogene by 68.5% in the first quarter. Vident Investment Advisory LLC now owns 83,868 shares of the biotechnology company’s stock worth $109,000 after buying an additional 34,082 shares in the last quarter. Hedge funds and other institutional investors own 1.71% of the company’s stock.

About Evogene

(Get Free Report)

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.

Recommended Stories

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.